ALPS Advisors’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
TP
ALPS Advisors's MRNA Position: Q3 2026 in Review
ALPS Advisors reduced its Moderna (MRNA) stake by 3.9% in Q3 2026, selling an estimated $17.8K and leaving 4,042 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #755.
ALPS Advisors first reported a position in MRNA in Q3 2021 and has held it in 8 quarters since. 1,044 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.
- ALPS Advisors held 4,042 shares of Moderna worth $778K as of Q3 2026.
- ALPS Advisors sold 165 Moderna shares in Q3 2026, an estimated $17.8K.
- Moderna made up ﹤0.01% of ALPS Advisors's portfolio in Q3 2026, its #755 holding.
- ALPS Advisors first reported a position in Moderna in Q3 2021 and has held it in 8 quarters since.
- 1,044 funds tracked by Wall St. Rank held Moderna as of Q3 2026.
Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.